Gastroenterology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Gastroenterology Search

Gastroenterology

Gastroenterology

Home News Diseases Conferences Special Reports Multimedia

Is stopping long-term nucleotide analogue treatment beneficial in chronic HBV?

Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Low-dose antidepressant effective for refractory functional dyspepsia

Dr. Joseph Delano Fule Robles, 3 days ago

A study by the Chinese University of Hong Kong (CUHK) has recently shown that low-dose imipramine, a tricyclic antidepressant (TCA), is efficacious for patients with functional dyspepsia not responsive to standard treatment with proton pump inhibitors (PPIs) or prokinetics.

Elderly patients with mCRC may benefit from reduced-dose S-1 + oxaliplatin over full-dose S-1 monotherapy

Roshini Claire Anthony, 6 days ago

Elderly, vulnerable patients with metastatic colorectal cancer (CRC) experienced longer progression-free survival (PFS) and fewer toxicities with a reduced-dose combination chemotherapy regimen of S-1 and oxaliplatin compared with full-dose S-1 monotherapy, the phase II NORDIC9* trial showed.

MIMS Gasteroenterology Supplement June 2018

19 Jun 2018

There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.

GPs in co-management of IBD: The follow-up phase

02 Oct 2017

Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.

An update on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

29 Sep 2017

Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.

The gentle approach towards effective management of constipation

29 Sep 2017

Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.¹ Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.

Challenges in the Medical Management of Reflux Symptoms: What’s New?

20 Mar 2017

At the recent Asian Pacific Digestive Week (APDW) 2016 held in Kobe, Japan, three prominent international experts shared their views on gastroesophageal reflux disease (GERD) and the challenges of its management.

Post-marketing data reaffirm vedolizumab safety in real world

Pearl Toh, 28 Jan 2019

The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.

Low rate of C. difficile infection in UC patients on tofacitinib

Roshini Claire Anthony, 28 Jan 2019

The incidence of Clostridium difficile (C. difficile) infection among patients with ulcerative colitis (UC) who are receiving treatment with tofacitinib is low and particularly so when compared with C. difficile infection incidence in patients receiving other UC therapies, according to a poster presented at AIBD 2018.

Paediatric-onset IBD tied to more severe disease course

Elaine Soliven, 25 Jan 2019

Patients with paediatric-onset inflammatory bowel disease (pIBD) have a higher incidence of severe IBD than those with adult-onset IBD (aIBD), according to a study presented at AIBD 2018.

Older age a risk factor for AEs during ulcerative colitis treatment

Elaine Soliven, 23 Jan 2019

Older patients receiving treatment for ulcerative colitis (UC) were more likely to experience adverse events (AEs) compared with their younger counterparts, according to a study presented at AIBD 2018.

High intra-, postoperative complication risks in patients with obesity and ulcerative colitis

Roshini Claire Anthony, 22 Jan 2019

Patients with obesity have an elevated risk of intra- and postoperative complications following surgical treatment for inflammatory bowel disease (IBD), according to a presentation at the recent Advances in Inflammatory Bowel Disease meeting (AIBD 2018).

Vedolizumab a “new chapter” for IBD therapy beyond anti-TNF

Pearl Toh, 21 Jan 2019

The α4β7 integrin antibody vedolizumab continues to show efficacy and safety in patients with inflammatory bowel disease (IBD) in an era beyond tumour necrosis factor (TNF) inhibitors, according to a presentation at the annual Advances in Inflammatory Bowel Diseases (AIBD) 2018 meeting.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!